InvestorsHub Logo
Followers 58
Posts 10142
Boards Moderated 1
Alias Born 09/21/2016

Re: None

Wednesday, 02/07/2018 9:47:59 AM

Wednesday, February 07, 2018 9:47:59 AM

Post# of 462078

“We believe Anavex is pioneering the inclusion of advanced genomic biomarkers into late-stage CNS precision medicine trials, including our Rett syndrome, Alzheimer’s disease and Parkinson’s disease trials. It was a strategic decision to start the new clinical trials after genetic data were collected and analyzed. We are expecting to leverage these important findings to more precisely target patients based on specific genomic profiles that may be highly responsive to ANAVEX®2-73,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. “This should allow us to improve upon existing trial designs and expedite other aspects of our clinical development program.”



Drops mic. IMO, there is no question this is the right direction to go in. Will AVXL be able to pull it off as stated?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News